mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19

Yan Tang; David J Kwiatkowski; Elizabeth P Henske

doi:10.1183/13993003.02737-2020

mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19

Eur Respir J. 2021 Feb 11;57(2):2002737. doi: 10.1183/13993003.02737-2020. Print 2021 Feb.

Authors

Yan Tang¹, David J Kwiatkowski^{1

2}, Elizabeth P Henske^{1

2}

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
² D.J. Kwiatkowski and E.P. Henske contributed equally to this article as lead authors and supervised the work.

Abstract

Increased pneumocyte expression of the SARS-CoV-2 entry receptor ACE2 in lymphangioleiomyomatosis (LAM) is associated with upregulation of interferon pathways in natural killer cells as well as increased IL6 expression in LAM-associated fibroblasts https://bit.ly/34ChSsg

Publication types

Letter

MeSH terms

Alveolar Epithelial Cells* / metabolism
Alveolar Epithelial Cells* / pathology
Angiotensin-Converting Enzyme 2 / genetics*
Antibiotics, Antineoplastic / pharmacology
COVID-19* / metabolism
COVID-19* / virology
Cancer-Associated Fibroblasts / metabolism
Humans
Interferons / metabolism
Interleukin-6 / metabolism
Lymphangioleiomyomatosis* / metabolism
Lymphangioleiomyomatosis* / pathology
Mechanistic Target of Rapamycin Complex 1 / metabolism*
SARS-CoV-2 / physiology
Signal Transduction / drug effects
Sirolimus / pharmacology*
Up-Regulation / drug effects

Substances

Antibiotics, Antineoplastic
IL6 protein, human
Interleukin-6
Interferons
Mechanistic Target of Rapamycin Complex 1
ACE2 protein, human
Angiotensin-Converting Enzyme 2
Sirolimus

Grants and funding

P01 CA120964/CA/NCI NIH HHS/United States